These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1578 related items for PubMed ID: 26893541

  • 1. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 2. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C, Schell LK, Rücker G, Allert R, Motschall E, Niemeyer CM, Bassler D, Meerpohl JJ.
    Cochrane Database Syst Rev; 2017 Aug 15; 8(8):CD007476. PubMed ID: 28809446
    [Abstract] [Full Text] [Related]

  • 3. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ.
    Hemoglobin; 2008 Aug 15; 32(1-2):1-15. PubMed ID: 18274978
    [Abstract] [Full Text] [Related]

  • 4. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Aug 15; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 5. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Kontoghiorghes GJ.
    Hemoglobin; 2006 Aug 15; 30(2):329-47. PubMed ID: 16798657
    [Abstract] [Full Text] [Related]

  • 6. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Aug 15; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 7. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
    Kontoghiorghes GJ, Spyrou A, Kolnagou A.
    Hemoglobin; 2010 Jun 15; 34(3):251-64. PubMed ID: 20524815
    [Abstract] [Full Text] [Related]

  • 8. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D.
    Cochrane Database Syst Rev; 2012 Feb 15; (2):CD007476. PubMed ID: 22336831
    [Abstract] [Full Text] [Related]

  • 9. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
    Xia S, Zhang W, Huang L, Jiang H.
    PLoS One; 2013 Feb 15; 8(12):e82662. PubMed ID: 24376563
    [Abstract] [Full Text] [Related]

  • 10. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
    Kolnagou A, Kontoghiorghes GJ.
    Front Biosci (Landmark Ed); 2018 Jan 01; 23(6):1082-1098. PubMed ID: 28930590
    [Abstract] [Full Text] [Related]

  • 11. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep 01; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 12. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ, Kolnagou A.
    Haematologica; 2006 Jun 01; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [Abstract] [Full Text] [Related]

  • 13. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun 01; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 14. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A.
    Transfus Sci; 2000 Dec 01; 23(3):211-23. PubMed ID: 11099897
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov 01; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 16. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ, Antes G, Rücker G, Fleeman N, Niemeyer C, Bassler D.
    Cochrane Database Syst Rev; 2010 Aug 04; (8):CD007477. PubMed ID: 20687088
    [Abstract] [Full Text] [Related]

  • 17. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
    Ricchi P, Marsella M.
    Drug Des Devel Ther; 2015 Aug 04; 9():6475-82. PubMed ID: 26719673
    [Abstract] [Full Text] [Related]

  • 18. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ.
    Cochrane Database Syst Rev; 2018 May 08; 5(5):CD012349. PubMed ID: 29737522
    [Abstract] [Full Text] [Related]

  • 19. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ.
    Hemoglobin; 2009 May 08; 33(5):332-8. PubMed ID: 19814679
    [Abstract] [Full Text] [Related]

  • 20. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep 08; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 79.